“Obsidian’s technology has the potential to unlock the activity of cell therapy in a number of new settings, particularly against solid tumor malignancies, and this is a prime example of the new technologies that we see enabling broader applications for CAR-T and cell therapies for the treatment of cancer,” said Celgene executive vice president for business development and global alliances Robert Hershberg, in a statement. Celgene has announced immuno - oncology partnerships with Kyn , and Obsidian , just weeks after being bought by Bristol - Myers Squibb for $ 1 . Celgene will pay Kyn $ 100 m and make an investment giving it the option of licensing development programmes , Roche ’s aryl hydrocarbon receptor antagonist and its Kynase product . It will also pay Obsidian an undisclosed sum together with an equity investment entitling it to future milestone payments and royalties . The partnerships mean Celgene could gain the rights to cell therapy product lines containing CD40L to help treat cancer .
Celgene has announced immuno - oncology partnerships with Kyn , and Obsidian , just weeks after being bought by Bristol - Myers Squibb for $ 1 . Celgene will pay Kyn $ 100 m and make an investment giving it the option of licensing development programmes , Roche ’s aryl hydrocarbon receptor antagonist and its Kynase product . It will also pay Obsidian an undisclosed sum together with an equity investment entitling it to future milestone payments and royalties . The partnerships mean Celgene could gain the rights to cell therapy product lines containing CD40L to help treat cancer .